Molecular targeting of CDK9 in oncology therapeutics: avenues for translational impact
- 25 August 2026
- journal article
- other
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 30 (9) , 929-940
Abstract
1. Cyclin-dependent kinases (CDKs) constitute a fundamental family of serine/threonine kinases whose catalytic activation is strictly contingent upon binding to specific regulatory subunits termed ...Keywords
This publication has 70 references indexed in Scilit:
- Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myelomaBlood Neoplasia, 2024
- CDK9 inhibitors for the treatment of solid tumorsBiochemical Pharmacology, 2024
- Predicting and overcoming resistance to CDK9 inhibitors for cancer therapyActa Pharmaceutica Sinica B, 2023
- Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trialsClinical and Translational Oncology, 2021
- CDK9: A key player in cancer and other diseasesJournal of Cellular Biochemistry, 2017
- Cyclin dependent kinase (CDK) inhibitors as anticancer drugsBioorganic & Medicinal Chemistry Letters, 2015
- Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell LymphomaCancer Cell, 2013
- Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity GenesCell, 2013
- Cancer Epigenetics: From Mechanism to TherapyCell, 2012
- Identification and Characterization of MAVS, a Mitochondrial Antiviral Signaling Protein that Activates NF-κB and IRF3Cell, 2005